Alimera Sciences (ALIM) Misses Q2 EPS by 2c

Alimera Sciences (NASDAQ: ALIM) reported Q2 EPS of ($0.06), $0.02 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $27 million versus the consensus estimate of $25.81 million.

For earnings history and earnings-related data on Alimera Sciences (ALIM) click here.

You May Also Be Interested In

• EyePoint Pharmaceuticals (EYPT) call put ratio 1.4 calls to 1 put as share price up 8.9%
• Klarna Group (KLAR) 46K contracts trade, share price down 21.5%
• Amylyx Pharmaceuticals (AMLX) 19K contracts trade